The recent in vivo studies regarding different applications (pulmonary sepsis, ARDS, allergic asthma, pulmonary fibrosis) strengthen the clinical data of EXO-CD24 in ARDS, its superiority over steroids, and the use of EXO-CD24 as a platform for urgent unmet treatment needs. This evidence concerns the gene CD24 and pulmonary fibrosis.